Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) ~~Compounds~~ A compound of ~~the general~~ formula (II)



Formula (II)



Formula (II)

in which R_1, R_2 either are the same or different and represent:

[[•]] hydrogen, F, Cl, Br, I, CN, NC, OH, SH, NO_2, SO_3H, NH_2, CF_3[[,]]; ~~or~~

[[•]] ~~substituted or unsubstituted~~ straight or branched lower (C_1-C_6) alkyl or alkoxy; ~~or~~

[[•]] an amino group substituted by one or more ~~substituted or unsubstituted~~ straight or branched lower (C_1-C_6) alkyl or alkyl carbonyl or alkoxy carbonyl group; ~~or~~

[[•]] a COOH, COO alkyl, ~~CONH, CON alkyl~~ $CONH_2$, $CON(alkyl)_2$ group; ~~or~~

[[•]] $-(CH_2)_n$-Cl, $-(CH_2)_n$-Br, $-(CH_2)_n$-OH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-CN, $-(CH_2)_n$-NC [[,]] ~~in which~~;

[[•]] R_1-R_2 may together form -CH=CH-CH=CH-, -O-$(CH_2)_n$-O-, with n=1 to 3;

R_3 is ~~OCH_3 or~~ the same as R_1, or

R_2-R_3 can jointly form[[:]] -O-$(CH_2)_n$-O-, with [[N]] n=1 to 3;

R_4, R_5[[:]] are ~~both~~ each independently hydrogen, ~~or, alternatively, any combination of hydrogen or~~ an alkyl, alkenyl, alkinyl[[,]]; ~~or~~

[[•]] S-R_8, wherein R_8 is hydrogen, or a ~~substituted or unsubstituted~~ straight or branched lower (C_1 -C_{10}) alkyl group;

[[•]] SO-R_8, SO_2R_8;

[[•]] OH, or OH substituted for H with an O-protective group;

[[•]] O-CS-N-R_8; ~~(thiourethanes)~~

[[•]] O-CO-N-R_9, wherein R_9 has the following meaning:





[[•]] O-CO-R_8[[,]]; ~~including esters with a substitution pattern of amino acids as follows~~







[[•]] R_4, R_5 may jointly be ~~hydrazone (=N-NH-R_{10}, =N-N (R_{10}, R_{11}),~~ ~~oximes (=N-O-R_{11})~~ =N-NH-R_{10}, =N-N$R_{10}R_{11}$, or =N-O-R_{11}, wherein R_{10} is hydrogen, ~~a substituted or unsubstituted~~ straight or branched lower (C_1-C_6) alkyl or alkyl carbonyl or alkyl carbonyloxy group ~~as well as a sulfonic acid group~~ or –SO_3H, and R_{11} is hydrogen, ~~a substituted or unsubstituted~~ straight or branched lower (C_1-C_6) alkyl or alkyl carbonyl group, ~~as well as a sulfonic acid group~~ or –SO_3H;

[[•]] R_4 and R_5 may also be:





, wherein [[Y_1, Y_2 =]] Y_1 is O, S, NH or N-R_{10} and Y_2 is –OH, -SH, -NH_2 or –NHR_{10}; ~~(excess valences in each case are H)~~

[[•]] ~~wherein, in the event that R_4 is not H, R_5 can also be OH and, in the event that R_5 is not H, R_4 can also be OH.~~

G_1, G_2[[:]] jointly or separately have the meaning:

[[• -C(R_{13}, R_{14})-]] -C($R_{13}$$R_{14}$)-, wherein R_{13}, R_{14} ~~can be~~ are each independently hydrogen, OH, a ~~substituted or unsubstituted~~ straight or branched lower alkyl, aryl, alkoxy or aryloxy group ~~or jointly an alkyl spiro group (C_3 to C_7 spiro ring).~~;

[[•]] G_1 and G_2 may jointly represent



with m=1 to 7;

G_1 and G_2 may jointly represent a C_3 to C_7 alkyl spiro ring group;

G_3[[:]] represents CH_2 or =CO;

R_6 represents a group $-(G_4)_p-(G_5)_q-G_6$ with p, q = 0-1, in which G_4 satisfies the following definition:

[[•]] $-(CH_2)_s-$, ~~$-C(R_{15}, R_{16})-(CH_2)_s-$, with R = 1 to 6~~ $-C(R_{15}, R_{16})-(CH_2)_s-$, with s = 1 to 6 and R_{15}, R_{16} [[=]] are each independently hydrogen, ~~or substituted or unsubstituted~~ straight or branched lower alkyl, cycloalkyl, or aryl groups;

[[•]] -O- or $-NR_{15}$;

[[•]] 

wherein s = 1-4, and t = 0-4;

[[•]] 

~~, that is an ortho, meta or para disubstituted aromatic~~ ; or

[[•]] 

,

wherein $G_7 = NR_{15}$, O or S[[,]];

G_5 can be identical with or different from G_4 and, in the event that [[P]] p = 1, additionally represents -S-[[,]];

G_6 fulfills the following definition:

[[•]] 

wherein

[[•]] R_{17}, R_{18}, R_{19} and R_{20} individually or jointly are the same or different, and are hydrogen, ~~substituted or unsubstituted~~ straight or branched lower alkyl, cycloalkyl or aryl groups, where R_{17} and R_{18} and R_{19} and R_{20} can jointly form a cycloalkyl group (with a ring size of 3-8);

[[•]] G_8 [[=]] is O, S, NH, NR_{21}-$(CH_2)_n$-[[,]];

[[•]] R_{21} [[=]] is CHO[[,]]; $COOR_{17}$[[,]]; ~~or~~ a heteroaryl group selected from the group consisting of 2-pyridyl, 4-pyridyl, and 2-pyrimidinyl, which is unsubstituted or substituted identically or differently by one or several F, Cl, Br, I, NO_2, OH, alkyl, alkyloxy, CN, NC or CF_3, CHO, COOH, COO alkyl, SO_3H, SH or S-alkyl groups[[,]]; or [[•]] a methyl group, which is substituted by 1-3 phenyl groups, which are unsubstituted or substituted identically or differently by one or more F, Cl, Br, I, NO_2, NH_2, alkyl, alkyloxy, CN, NC or CF_3 groups[[,]];

wherein [[G_8]] $\underline{G_6}$ can also be:



~~or~~ ,

[[•]]  ,  ,  ,





,

[[•]]  .

[[•]] –CHO, $COOR_{17}$, or $–CONR_{17}$;

[[•]] a ~~substituted or unsubstituted~~ straight or branched lower alkyl, alkenyl, alkinyl, cycloalkyl or aryl groups[[,]]; or

[[•]] -O-R_{17}, -$NR_{17}R_{18}$ phthalamido, -CN or -NC;

~~R_7 is identical with R_6 or represents -O-$^{(-)}$ (N-oxide) or a free electron pair (e-pair), wherein R_6 and R_7 can also form a common ring, 3 to 8 carbon atoms in size and~~

[[•]] X ~~exists only if, and~~ represents an ion of a pharmacologically unstable inorganic or organic acid~~, where R_5 and R_6 are present and the nitrogen atom thus carries a positive charge~~; and

[[•]] Z [[=]] ~~N or~~ is N^+ ~~in the event that R_4 and R_7 are present jointly and R_7 are present jointly and R_7 is not O~~[[⁻]].[[--]]

Claims 2 to 7 (Canceled).

8. (New) A compound of claim 1, wherein R_3 is OCH_3.

9. (New) A composition comprising a compound of claim 1 in admixture with a pharmaceutically acceptable excipient.

10. (New) A method for treating Alzheimer's disease comprising administering to a human patient in need thereof a pharmaceutically acceptable amount of a compound of claim 1.